中國中藥(00570.HK)盈警:預計中期溢利同比下降165%-175%
格隆匯7月25日丨中國中藥(00570.HK)發佈公告,集團預計截至2025年6月30日止六個月溢利淨額同比下降165%-175%。
董事會認爲,集團本期溢利淨額下降主要原因爲:(i)中藥配方顆粒業務受集採業務佔比增加、市場競爭加劇等影響,收入規模及盈利能力下降;及(ii)因中藥配方顆粒業務經營業績不達預期,就該業務資產組進一步計提商譽減值。
董事會強調,上述計提商譽減值屬非現金性質,乃爲使集團財政狀況未來可取得改善而採取的必要措施。上述減值對集團現金流量或業務及生產營運並無任何影響。若扣除商譽減值的影響,預計集團本期仍有盈利,但較2024年同期同比下降50%-60%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.